The startup develops topical dermatological therapies targeting conditions such as androgenetic alopecia, plaque psoriasis, and atopic dermatitis. By providing healthcare professionals with effective treatment options, the company enhances patient outcomes in skin health and hair growth.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for dermatological conditions like androgenetic alopecia and plaque psoriasis often have limited efficacy, suboptimal safety profiles, and/or require lengthy and costly development processes. The discovery-to-market pathway for new drugs can take over a decade and billions of dollars, with a low probability of success.
Solution
BioResearch Pharma (BRP) addresses these challenges by focusing on the repurposing of existing drugs for dermatological applications, significantly reducing the time, risk, and cost associated with bringing new treatments to market. BRP leverages active pharmaceutical ingredients with confirmed safety profiles to develop novel topical therapies for conditions with unmet medical needs. This approach allows for faster regulatory pathways and a higher probability of success compared to developing new chemical entities. BRP's pipeline includes BRP-011, a topical treatment for androgenetic alopecia based on latanoprost acid, and BRP-007, a topical anti-inflammatory treatment for skin diseases like plaque psoriasis based on cefazolin.
Target Audience
The primary target audience includes patients suffering from androgenetic alopecia, plaque psoriasis, and atopic dermatitis, as well as healthcare professionals seeking safer, more effective, and cost-efficient topical treatment options.
Features
- Utilizes drug repurposing strategy to accelerate development and reduce costs.
- BRP-011: Topical application of latanoprost acid to promote hair growth in androgenetic alopecia, with a patent filed. Latanoprost acid is a more potent agonist of the PGFα receptor than latanoprost.
- BRP-007: Topical cefazolin as an anti-inflammatory agent for psoriasis and atopic dermatitis, inhibiting pro-inflammatory cytokines. Patented for use in psoriasis in the US, EU, and Australia.
- Investigational products have the potential for use in multiple major dermatology indications.
- Aims for a "3x less" principle: less time, less risk, and less cost compared to new chemical entities.